Pancoast Tumors: 11-Year Single-Centre Experience
DOI:
https://doi.org/10.48729/pjctvs.438Keywords:
Superior sulcus tumor, Pancoast tumor, Shaw-Paulson, Thoracotomy, SurgeryAbstract
Introduction: Pancoast tumors encompass any tumor located on the lung apex, extending into structures in the thoracic inlet and, often, leading to the characteristic clinical syndrome. The main goal of this study is to analyze the response to multimodal treatment and outcome of patients with Pancoast tumors.Materials and Methods: We performed a retrospective cohort single center study of patients with superior sulcus nonsmall cell lung carcinomas who underwent surgery between January of 2011 and February of 2022.
Results: A total of ten patients were considered, 80,0% were male with a mean age of 53,6 (±6,6) years. At diagnosis, two tumors were stage II and eight were stage III. Histopathology revealed eight were adenocarcinomas and two were sarcomatoid carcinomas. All patients underwent neoadjuvant treatment before surgery. Nine patients received lung lobectomy, with en bloc resection comprising, predominantly, the chest wall (80,0%) and brachial plexus (30,0%). In one patient, surgery was aborted. Surgical histopathology showed free surgical margins were achieved in eight patients (80,0%). Two patients achieved full tumoral remission (ypT0N0, 22,2%), two tumors were stage I (22,2%), two were stage II (22,2%), two were stage III (22,2%) and one tumor was stage IV (11,1%). Mean disease-free survival was 83,9 (CI95% 42,1-125,8) months. 3-month disease-free survival rate was 88,9% and 1-year and 5-year disease-free survival rates were 63,5%. After the first-year follow-up, there was no evidence of disease progression. Mean overall survival was 115,7 (CI95% 89,3-142,1) months. At 3-month, 1-year and 5-years, overall survival was 88,9%.
Conclusion: Although considering the small sample of patients, the survival of Pancoast tumors in our institution exhibits a positive outcome, when compared to current literature, Significant improvements have been reported recently, in understanding the nature of Pancoast tumors, emphasizing the importance of a multidisciplinary approach but still, further research is required.
Downloads
References
Panagopoulos N, Leivaditis V, Koletsis E, Prokakis C, Alexopoulos P, Baltayiannis N, et al. Pancoast tumors: Characteristics and preoperative assessment. J Thorac Dis 2014;6. https://doi.org/10.3978/j.issn.2072-1439.2013.12.29.
Palumbo VD, Fazzotta S, Fatica F, D’Orazio B, Caronia FP, Cajozzo M, et al. Pancoast tumour: Current therapeutic options. Clínica Terapêutica 2019;170:E291–4. https://doi.org/10.7417/CT.2019.2150.
Hao X, Wang Z, Cheng D, Zhou J, Chen N, Pu Q, et al. The Favorable Prognostic Factors for Superior Sulcus Tumor: A Systematic Review and Meta-Analysis. Front Oncol 2020;10. https://doi.org/10.3389/fonc.2020.561935.
Foroulis CN, Zarogoulidis P, Darwiche K, Katsikogiannis N, Machairiotis N, Karapantzos I, et al. Superior sulcus (Pancoast) tumors: Current evidence on diagnosis and radical treatment. J Thorac Dis 2013;5. https://doi.org/10.3978/j.issn.2072-1439.2013.04.08.
Ettinger DS, Wood DE, Chair V, Aisner DL, Akerley W, Bauman JR, et al. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer NCCN Guidelines Panel Disclosures 2022.
Archie VC, Thomas CR. Superior Sulcus Tumors: A Mini-Review. Oncologist 2004;9:550–5. https://doi.org/10.1634/theoncologist.9-5-550.
Nikolaos P, Vasilios L, Efstratios K, Panagiotis A, Christos P, Nikolaos B, et al. Therapeutic modalities for Pancoast tumors. J Thorac Dis 2014;6. https://doi.org/10.3978/j.issn.2072-1439.2013.12.31.
Solli P, Casiraghi M, Brambilla D, Maisonneuve P, Spaggiari L. Surgical Treatment of Superior Sulcus Tumors: A 15-Year Single-center Experience. Semin Thorac Cardiovasc Surg 2017;29:79–88. https://doi.org/10.1053/j.semtcvs.2017.01.010.
Rusch VW, Parekh KR, Leon L, Venkatraman E, Bains MS, Downey RJ, et al. Factors determining outcome after surgical resection of T3 and T4 lung cancers of the superior sulcus. Journal of Thoracic and Cardiovascular Surgery 2000;119:1147–53. https://doi.org/10.1067/mtc.2000.106089.
Truntzer P, Antoni DN, Santelmo N, Schumacher C, Falcoz PE, Quoix E, et al. Superior sulcus non small cell lung carcinoma: retrospective analysis of 42 patients. Radiat Oncol 2014;9:259. https://doi.org/10.1186/s13014-014-0259-6.
Attar S, Krasna MJ, Sonett JR, Hankins JR, Slawson RG, Suter CM, et al. Superior Sulcus (Pancoast) Tumor: Experience With 105 Patients. Ann Thorac Surg 1998; 66:193– 8. https://doi: 10.1016/s0003-4975(98)00374-9
Martins F, Silva A, Bernardo J, Antunes MJ. Cirurgia dos Tumores de Pancoast. Casuística de um Centro de Cirurgia Cardiotorácica. RevPort Cir Cardiotorac 2015; 22:97-100
Shanmugathas N, Rajwani KM, Dev S. Pancoast tumour presenting as shoulder pain with Horner’s syndrome. BMJ Case Rep 2019;12. https://doi.org/10.1136/bcr-2018-227873.
Komaki R, Roth JA, Walsh GL, Putnam JB, Vaporciyan A, Lee JS, et al. Outcome Predictors for 143 Patients with Superior Sulcus Tumors Treated By Multidisciplinary Approach at The University of Texas. Int. J. Radiation Oncology Biol. Phys 2000; 48:347–354. https://doi: 10.1016/s0360-3016(00)00736-7
Lin TYY, Atrchian S, Humer M, Siever J, Lin A. Clinical outcomes of Pancoast tumors treated with trimodality therapy. J Thorac Dis 2021;13:3529–38. https://doi.org/10.21037/jtd-21-380.
Couto WJ, Suelotto RR, Filho UP, Guimarães JRQ, Peres ALM. Diagnóstico e recentes avanços no manuseio dos tumores do sulco superior do pulmão: revisão de literatura. Revista Brasileira de Cancerologia 2006;52:381–6. https://doi.org/10.32635/2176-9745.rbc.2006v52n4.1853.
Kunitoh H, Kato H, Tsuboi M, Shibata T, Asamura H, Ichonose Y, et al. Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small cell lung cancers: Report of Japan clinical oncology group trial 9806. Journal of Clinical Oncology 2008;26:644–9. https://doi.org/10.1200/JCO.2007.14.1911.
Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T, et al. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: Long-term results of Southwest Oncology Group trial 9416 (Intergroup trial 0160). Journal of Clinical Oncology 2007;25:313–8. https://doi.org/10.1200/JCO.2006.08.2826.
Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Johnson D, et al. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group trial 9416 (Intergroup trial 0160). Journal of Thoracic and Cardiovascular Surgery 2001;121:472–83. https://doi.org/10.1067/mtc.2001.112465.
Tamura M, Hoda MA, Klepetko W. Current treatment paradigms of superior sulcus tumours. European Journal of Cardio-Thoracic Surgery 2009;36:747–53. https://doi.org/10.1016/j.ejcts.2009.04.036.
Ortega MA, Pekarek L, Navarro F, Fraile-Martínez O, García-Montero C, Álvarez-Mon MÁ, et al. Updated Views in Targeted Therapy in the Patient with Non-Small Cell Lung Cancer. J Pers Med 2023;13. https://doi.org/10.3390/jpm13020167.
Tang WF, Xu W, Huang WZ, Lin GN, Zeng YM, Lin JS, et al. Pathologic complete response after neoadjuvant tislelizumab and che-
motherapy for Pancoast tumor: A case report. Thorac Cancer 2021;12:1256–9. https://doi.org/10.1111/1759-7714.13910.
Barata F, Fidalgo P, Figueiredo S, Tonin FS, Duarte-Ramos F. Limitations and perceived delays for diagnosis and staging of lung cancer in Portugal: A nationwide survey analysis. PLoS One 2021;16. https://doi.org/10.1371/journal.pone.0252529.
Popat S, Navani N, Kerr KM, Smit EF, Batchelor TJP, Van Schil P, et al. Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach. Oncologist 2021;26:e306–15. https://doi.org/10.1002/onco.13586.
Downloads
Published
How to Cite
License
Copyright (c) 2024 Portuguese Journal of Cardiac Thoracic and Vascular Surgery
This work is licensed under a Creative Commons Attribution 4.0 International License.
